Part No: P169Issued year: 2017File size: 0.23mbFile type: pdf
Improvements in solid phase peptide synthesis strategies and
development of resin linkages susceptible to low acid cleavage
conditions has enabled synthesis of long peptides while keeping the
protecting groups intact. This strategy is now used for the
preparation of chemically synthesized proteins, wherein shorter
peptide fragments are ligated together. They are also found in the
synthesis of peptide macrocycles that utilize head-to-tail cyclization strategies. Although linear synthesis of protected peptides is generally straightforward, purification of these compounds using traditional reversed phase methods is quite challenging. Herein we describe the use of normal phase chromatography for purification of fully protected peptides.
Part No: AN886Issued year: 2017File size: 1mbFile type: pdf
This application note describes the extraction of 96 licit and illicit drugs of abuse from urine prior to UPLC-MS/MS analysis using EVOLUTE® HYDRO CX 96-well plates.
EVOLUTE® HYDRO CX plates offer an efficient way to perform hydrolysis in the well of the extraction plate. This method provides high analyte recovery, reduced extraction time due to the elimination of a sample transfer step as well as the elimination of the column conditioning and equilibration steps, and a reduced risk for sample carryover or cross-contamination due to the elimination of the sample transfer step.
Part No: AN863Issued year: 2016File size: 1.62mbFile type: pdf
This application note describes the use of ISOLUTE® ENV+ on-line cartridges in a fully automated on-line SPE-LC-MS/MS method for extraction and quantification of 16 acid herbicides in drinking and surface water.
Part No: SSI-LCMS-086Issued year: 2017File size: 0.37mbFile type: pdf
Catecholamines and Metanephrines were analyzed using a LCMS-8060 triple quadrupole mass spectrometer. Calibrators were prepared in synthetic urine and extracted using solid phase extraction. Extractions were performed using weak cation exchange on the EVOLUTE® EXPRESS WCX 10 mg 96-well plate from Biotage.
Part No: P164Issued year: 2017File size: 0.69mbFile type: pdf
Most drugs, both licit and illicit, are excreted in urine as glucuronide conjugates. Hydrolysis using beta-glucuronidase converts the glucuronidated metabolites back to their “free” or non-conjugated
form, increasing sensitivity for LC-MS/MS analysis. Hydrolysis using red abalone, abalone, and recombinant beta-glucuronidase enzymes was evaluated using an in-well hydrolysis plate to determine which provided the most efficient hydrolysis of glucuronide metabolites without affecting overall recovery of nonconjugated compounds. A glucuronide control containing 8 glucuronide compounds was used to determine the extent of hydrolysis that occurred. A non-conjugated control containing 96 licit and illicit drugs of abuse was evaluated to determine if signal suppression occurred as a result of enzyme hydrolysis.
Part No: AN862Issued year: 2016File size: 1.48mbFile type: pdf
This application note describes the use of EVOLUTE® EXPRESS ABN on-line cartridges in a fully automated on-line SPE-LC-MS/MS method for extraction and quantification of 13 commonly prescribed pharmaceuticals (with a range of characteristics) in water.
Part No: AN815Issued year: 2014File size: 1.52mbFile type: pdf
The method described in this application note achieves high recoveries of THC and an extended suite of common metabolites in oral fluid from Quantisal (Immunalysis) oral fluid collection devices.
This application note describes effective and efficient
ISOLUTE SLE+ protocols optimized for sample loading volumes of either 300 μL or 800 μL. The simple sample preparation procedure delivers clean extracts and analyte recoveries greater than 64% with RSDs of <10% for all analytes.
Part No: Issued year: 2016File size: 0.8mbFile type: pdf
Urine samples are neutralized using 0.5 M ammonium acetate and loaded onto weak cation exchange (WCX) Evolute Express plates (Biotage), preconditioned with methanol and water. Samples are washed with 20 mM ammonium acetate and water before elution in 0.5 % formic acid.
Department of Clinical Chemistry and Immunology, Heart of England NHS Foundation Trust, Birmingham, UK
Part No: Issued year: 2005File size: 1.78mbFile type: pdf
The cost-saving program that Biotage carried out and the synergistic effects that arose through the merger of Pyrosequencing, Personal Chemistry, and Biotage
LLC achieved almost full effect in the ﬁrst quarter. Operating costs were SEK 72m for the quarter, in line with the full year target of SEK 300m.
Part No: Issued year: 2006File size: 2.01mbFile type: pdf
Biotage has had an eventful 2005. We continued to strengthen the Discovery
Chemistry business area by acquiring the American company, Argonaut
Technologies and the Swiss company, Separtis. In the Biosystems business
area, our sequencing technology, Pyrosequencing, attracted a lot of attention
during the year, indicating that the technology is starting to strengthen its
position on the market.
Part No: Issued year: 2009File size: 1.78mbFile type: pdf
Biotage is a leading global supplier of solutions in medicinal chemistry. The company is also a well-established supplier of products in analytical
chemistry. Biotage’s shares are listed on the Nasdaq OMX Nordic Exchange small-cap list.
Part No: Issued year: 2010File size: 2.35mbFile type: pdf
Biotage is a leading global supplier of instruments and consumables for medicinal chemists. The Company is also a wellestablished supplier of products in analytical chemistry. Biotage’s shares are listed on the Nasdaq OMX Stockholm Small Cap list.
Part No: Issued year: 2011File size: 3.52mbFile type: pdf
Biotage is a leading global supplier of instruments and consumables
for medicinal chemistry. The Company is also a well-established
supplier of products in analytical chemistry. Promising products for
both separation and purification in production volumes are being
evaluated. Biotage’s shares are listed on the Nasdaq OMX Stockholm
Small Cap list
Part No: Issued year: 2012File size: 3.76mbFile type: pdf
Biotage offers instruments and consumables within three areas – organic chemistry, analytical chemistry and process chemistry. These products are used across the world in everything from pharmaceutical development to the analysis of samples within the environmental and food sectors. Biotage’s shares are listed on the NASDAQ OMX Stockholm Small Cap list.
Part No: Issued year: 2013File size: 1.52mbFile type: pdf
Biotage offers products and services within three areas – Organic Chemistry, Analytical Chemistry and Industrial Resins. The Company’s offering is oriented toward an international market, and the majority of the Company’s sales are generated outside Sweden. The Biotage share is listed on the NASDAQ OMX Stockholm Small Cap list.
Part No: TN0009.1205Issued year: 2005File size: 0.06mbFile type: pdf
Argoresin MP-Isocyanate is a macroporous polystyrene-bound scavenger, for nucleophiles such as amines and alkoxides. Resin bound scavengers are added after a reaction is complete in order to quench and react selectively with excess reactants and/or reaction byproducts. The resulting resin-bound reactants are removed by simple filtration.
Part No: TN0010.1205Issued year: 2006File size: 0.06mbFile type: pdf
Argoresin MP-TMT is a macroporous polystyrene-bound trimercaptotriazine,
a resin-bound equivalent of 2,4,6- trimercaptotriazine (TMT). The resin is
designed to scavenge residual palladium from products derived from palladium
catalyzed reactions.1 Despite the widespread use of palladium-mediated
reactions, removal of residual palladium during workup and product isolation remains a major problem. Reducing the palladium content to the low parts per million (ppm) levels, as is required for active pharmaceutical ingredients, is particularly challenging.
Part No: TN0008.1205Issued year: 2005File size: 0.06mbFile type: pdf
Argoresin MP-Trisamine is a macroporous polystyrene-bound scavenger,
for electrophiles such as acid chlorides, sulfonyl chlorides and isocyanates.
Resin bound scavengers are added after a reaction is complete in order to
quench and react selectively with excess reactants and/or reaction byproducts.
Part No: Issued year: 2004File size: 0.97mbFile type: pdf
Genom Pyrosequencings förvärv av Personal Chemistry och Biotage LLC under 2003 bildades det nya Biotage. Den nya konstellationen ger förutsättningar för en långsiktig lönsamhet på en kraftig och dynamisk tillväxtmarknad.
Part No: Issued year: 2006File size: 2.14mbFile type: pdf
2005 har varit ytterligare ett händelserikt år för Biotage. Vi har fortsatt arbetet med att stärka verksamheten inom affärsområdet Discovery Chemistry genom förvärvet av amerikanska Argonaut Technologies och schweiziska Separtis. Inom affärsområdet Biosystems har vår sekvenseringsteknologi, Pyrosequencing, fått mycket uppmärksamhet under året, ett tecken på att teknologin börjar stärka sin ställning på marknaden.